A surge in US Food and Drug Administration (FDA) rejections and delays has highlighted chemical, manufacturing and controls (CMC) as a major barrier to approval in cell and gene therapy development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback